List of Tarpeyo drug patents

Tarpeyo is owned by Calliditas.

Tarpeyo contains Budesonide.

Tarpeyo has a total of 1 drug patent out of which 0 drug patents have expired.

Tarpeyo was authorised for market use on 15 December, 2021.

Tarpeyo is available in capsule, delayed release;oral dosage forms.

Tarpeyo can be used as treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression.

The generics of Tarpeyo are possible to be released after 07 May, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8491932 CALLIDITAS Compositions for the oral delivery of corticosteroids
May, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 15, 2024

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 15 December, 2021

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in